论文部分内容阅读
Apoptin诱导人转化细胞而不是正常细胞的凋亡,特异性地感知转化细胞的信号并被激活。这些特性使得Apoptin成为一种用于与细胞转化相关的肿瘤以及自身免疫性疾病(如风湿性关节炎)的前景型制剂。不同研究小组相继报道了细胞转化特异性过程和Apoptin凋亡诱导的相关性,如肿瘤特异激酶激活以及p53阴性转化细胞中细胞分裂后期启动复合物(APC)即起关键作用。体内外前临床基因治疗研究和蛋白转导试验充分显示Apoptin作为治疗制剂的有效性和安全性。化疗药物,如etoposide、paclitaxel或methotrexate(甲氨蝶呤)与Apoptin的联合治疗,协同增强了对肿瘤细胞的毒效应。对Apoptin感知的细胞转化信号通路的深入研究,将有助于在分子水平上进一步揭示癌发生或风湿性关节炎疾病的病理机制。Apoptin工艺与其它化疗制剂的结合,将为细胞转化相关疾病提供新颖的治疗策略。
Apoptin induces apoptosis in human transformed cells rather than normal cells, specifically sensing transformed cells and activating them. These features make Apoptin a promising agent for tumors associated with cell transformation as well as autoimmune diseases such as rheumatoid arthritis. Different research groups have reported the correlation between cell-specific transformation and Apoptin induction of apoptosis, such as tumor-specific kinase activation and post-cell division initiation complex (APC) in p53-negative transformed cells. In vitro and in vivo clinical gene therapy studies and protein transduction assays have demonstrated the efficacy and safety of Apoptin as a therapeutic agent. Chemotherapy drugs such as etoposide, paclitaxel or methotrexate (methotrexate) in combination with Apoptin synergistically enhance the toxic effect on tumor cells. In-depth study of Apoptin-sensing cell transformation signaling pathways will help to further elucidate the molecular mechanism of the pathogenesis of cancer or rheumatoid arthritis. The combination of Apoptin technology with other chemotherapeutic agents will provide a novel therapeutic strategy for cell-associated diseases.